

# Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

2025-05-28

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida.

A live webcast of the fireside chat will be made available under **Events & Presentations** in the Investors section of the **Vir Biotechnology website** and will be archived for 30 days.

## About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

## Media

Corporate Communications, Vir Biotechnology  
[corporatecomms@vir.bio](mailto:corporatecomms@vir.bio)

## Investors

Richard Lepke  
Senior Director, Investor Relations

**rllepke@vir.bio**

Source: Vir Biotechnology, Inc.